Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3938_Библиотеки_им_академика_М_И_Перельмана
.pdf
338 Index
Superfi cial venous incompetence (SVI)
DVI v., 38
venous ulcer from, 36
Surgery
anatomic changes with, 140–143, 142f
with compression therapy
v. compression therapy alone, 135–146
concluding remarks on, 145–146
ESCHAR study, 136–145
other studies, 145
for GSV removal, 157–158
healing impact of, 137–140, 139f
hemodynamic changes with, 143–144,
144f
rationale for, 136
recurrence impact of, 140, 141f
superfi cial, for VLUs, 149–170
conventional ligation of IPVs, 166–169,
167f
GSV removal, 157–158
saphenofemoral ligation and
saphenous stripping, 158–160
saphenous stripping to ankle or knee,
160 –166
SVI. See Superfi cial venous incompetence
T
Tel an gi ecta se s
in pregnancy, 11
sclerotherapy and, 188
SF and, 193
varicose veins from, 8
Tessari method, for foam sclerotherapy,
178, 193, 208
Thermal techniques, for varicose veins, 195
Thrombin, inhibition by antithrombin,
57–58
Thromboembolism, with foam
sclerotherapy, 208
Thrombophilia conditions. See also
Acquired thrombophilia conditions;
Inherited thrombophilia conditions
summary of, 63–64
Thrombophlebitis
from EVLA, 182
with foam sclerotherapy, 208
Thromboprophylaxis
methods of, 118–126
fondaparinux, 121t, 124–125
LMWH, 121t, 122–124
mechanical, 121t, 125–126
UFH, 121t, 122
warfarin, 118–120, 121t
for VTE, 116–126
RAM for, 117–118, 119–120f
Thrombotic obstruction
acute, 282–283
chronic
iliac, 283, 284f
IVC, 284–290, 285–287t, 288–291f,
289t
non, 281–282, 282f
Thrombus formation, with leukocytes, 4
TIMP-2. See Tissue inhibitor
metalloproteinase-2
Tissue inhibitor metalloproteinase-2
(TIMP-2), in venous ulcers, 21
T-l ymphocy tes
in venous disease, 5
in venous ulcers, 19
TNF-α. See Tumor necrosis factor-α
Transcommissural valvuloplasty, for
venous valve repair, 249
Transforming growth factor beta (TGF-β)
in venous ulcer bed, 18
in venous ulcers, 6
Transient visual disturbance, with foam
sclerotherapy, 208–209
Transmural valvuloplasty, for venous valve
repair, 247–248
Treatment
DU for endovenous, 227–239
equipment for, 228
preoperative assessment for, 227–228
venous mapping for, 228–231, 229f
DU mapping for, 52, 231–234, 232–234f
superfi cial surgery and perforator
interruption in, 149–170
conventional surgical procedures,
157–169
CVI presentation, 149–150
diagnostic testing, 150–157
for VLUs, 200–201
Treatment adherence, in wound healing,
96–99
Trypsin, MMP activation by, 7–8
Tumor necrosis factor-α (TNF-α), in
venous ulcers, 5, 20
U
UFH. See Unfractionated heparin
Ulcer bed
https://t.me/med1917
Index 339
evaluation of, 51
negative pressure dressings for, 108
Ultrasound. See also Duplex ultrasound
for foam sclerotherapy, 178, 202, 216–218
SSV mapping with, 161
Unfractionated heparin (UFH), as
thromboprophylaxis, 121t, 122
Unna boot bandage. See Zinc paste
bandages
V
VAC . See Vacuum-assisted closure
Vacuum-assisted closure (VAC)
for CLUs, 307–324
concluding remarks on, 316f, 319t,
322–324, 323t
limitations of, 321–322
modes of action, 321
randomized clinical trial with CLUs and,
308–320
complications of, 320, 320t
cost analysis of, 312, 318–320, 320t
evaluation criteria for, 311
patient and ulcer characteristics in,
314f, 315
procedures for, 310–311
protocol violations in, 314f, 315
quality of life and pain scores in, 311–
312, 318, 319t
recruitment for, 314–315, 314f
secondary outcomes of, 317–318, 318f,
323t
setup, 309–310
statistical analysis of, 312–314, 313t,
316f, 317t, 318f
time consumption in, 312
VAC v. conventional wound care in,
315–317, 316f, 317t
use of, 308
for venous ulcers, 95
Valsalva maneuver, for duplex ultrasound,
44
Valvuloplast y, external
results of, 249, 250–251t, 254
for venous valve repair, 247–249
angioscopy-assisted, 249
transcommissural, 249
transmural, 247–249
Varicose vein s
foam sclerotherapy for, 216
POL for, 186
risk factors for, 173–174
SF treatment of, 195–196
surgery for SVI/DVI patients, 36
from telangiectases, 8
tissue restructuring in, 6
venous ulcers from, 27, 31
Vascular adhesion molecules (VCAM-1),
in leukocyte migration and activation,
19
Vascular endothelial growth factor
(VEGF)
in venous infl ammation, 5– 6
in venous ulcers, 20
VCAM-1. See Vascular adhesion molecules
VCSS. See Venous clinical severity score
VEGF. See Vascular endothelial growth
factor
Vein of Giacomini, SSV termination at,
161
Vein valve transplantation, for venous
valve repair, 246, 247f
Velcro-band gaiters, for venous ulcers, 84
Venous clinical severity score (VCSS), for
VLCs, 218
Venou s d isease. See Chronic venous
disease
Venou s fi lling index (VFI)
calculation of, 152–153, 153f
outcome prediction with, 154, 154f
Venou s hypert en sion (VH)
reversal of, 200–201
VLUs caused by, 199–200, 209–210, 261
Venou s i nsu ffi ciency, chronic,
microcirculation in, 15–23
Venou s l eg ulcer s (VLUs)
adjuvant therapy for, 93–95
allografts, 93–94
collagen dressings and growth factor
therapy, 95
HSEs, 94
VAC , 9 5
xenografts, 93
arterial insuffi ciency and, 299–305
clinical study review for, 303–305
concluding remarks on, 305
evaluation of, 299–302
treatment of, 302–303
cause of, 15–23, 149
arteriovenous shunting, 16
cytokines and growth factors, 20
diffusion barrier, 16–18
historical theories for, 15–16
https://t.me/med1917
340 Index
Venous leg ulcers (VLUs) (continued)
leukocytes and endothelial cells, 19–20
MMP, 21–22
oxidative stress, 20–21
summary of, 23
varicose veins, 27, 31
white cell trapping, 18–19
collaborative models for care of, 99–100
compression therapy for, 77–89
devices for, 77–86, 78t
from CVI, 55, 149–150
diagnostic testing for, 150–157
APG, 152–154, 153–154f
duplex ultrasound, 150–151
intervention indications with, 154–157,
155–156f, 157t
photoplethysmography, 151–152
epidemiology of, 27–39
age and sex distribution of, 35–36, 35f
description of, 27–28
DVT history in, 37
etiologic spectrum of leg ulcers,
30–31
future trends in, 38–39
healing and survival, 38, 38f
history for, 36–37, 36f
incidence of, 34
incidence v. prevalence, 28–30, 29t
obesity in, 37
prevalence of, 31–34, 32–34t
EVLA v. RFA, 164
fi broblasts in, 22
fl uids of, 21
foam sclerotherapy for, 146, 199–211,
215–223
comments on, 209–211, 221–223, 222f,
222t
contraindications for, 209
methods for, 202–203, 216–218, 217f
outcomes of, 203–207, 204–205f, 206t,
207f, 218–221, 219–220f, 219t
safety of, 208–209
statistical analysis of, 218
free tissue transfer, 261–272
concluding remarks on, 271–272
discussion of, 269–271
fl ap selection for, 266–267, 268f
overview of, 261–262, 264t
patient evaluation and selection for,
262–266
postoperative care for, 269
surgical technique for, 268–269
indications for intervention of, 154–157,
155–156f, 157t
management of, 91–93
MMP expression of, 7
negative pressure dressings in, 105–111
adjunct to assisted closure, 109–110
bacterial burden, 107–108
chronic wound fl uid, 106
concluding remarks on, 110–111
direct wound closure, 108
indications and contraindications, 110
local blood fl ow, 107
local edema, 106–107
wound bed deformation, 108
wound healing environment, 108–109
wound hypoxia, 109
overview of, 199
perforator veins in, 49–50
recurrence prevention of, 86
superfi cial surgery and perforator
interruption for, 149–170
diagnostic testing for, 150–151
superfi cial veins in, 46–49
surgery for, 136 –145, 157–169
healing impact of, 137–140, 139f
recurrence impact of, 140, 141f
TGF-β in, 6
TNF-α in, 5
treatment options for, 200–201
Venou s o bstruction
in CVI, 275–295
diagnosis and evaluation of, 278f, 281f
clinical presentation of, 277–280, 278f
imaging of, 280–281, 281f
endovenous therapy for
acute thrombotic obstruction, 282–283
chronic thrombotic obstruction: iliac,
283, 284f
chronic thrombotic obstruction: IVC,
284–290, 285–287t, 288–291f, 289t
concluding remarks on, 295
nonthrombotic obstruction, 281–282,
282f
special issues in, 290–294
endovenous treatment for, 281–294
Venou s refi ll time (VRT), after surgery,
143 –144, 144f
Venous segment transfer, for venous valve
repair, 244–246, 246f
Venous stasis ulceration (VSU)
clinical study review for, 303–305
concluding remarks on, 305
https://t.me/med1917
Index 341
evaluation of, 299–302
arteriography and venography,
301–302
history and physical examination,
299–301
vascular laboratory testing, 301
prevalence of, 299
treatment of, 302–303
Venous thromboembolism (VTE)
risk of, 114–116
thromboprophylaxis for, 116–126
methods of, 118–126
RAM for, 117–118, 119–120f
Venous thrombosis, antiphospholipid
syndrome and, 58t, 60–61
Venous valve repair, in CVI, 243–255
concluding remarks on, 255
indications for, 254–255
according to etiology, 255
clinical severity, 254
hemodynamics and imaging, 254–255
methods for, 244–249
with phlebotomy, 244–247, 245–248f
without phlebotomy, 247–249
rationale for, 244
results of, 249, 250–253t, 254
primary deep vein refl ux, 249,
250–251t, 254
PTS, 252–253t, 254
Venous volume (VV), measurement of,
152, 153f
VFI. See Venous fi lling index
VH. See Venous hypertension
Vitronectin, degradation of, 21
VLUs. See Venous leg ulcers
VRT. See Venous refi ll time
VSU. See Venous stasis ulceration
VTE. See Venous thromboembolism
VV. See Venous volume
W
Wal lstent, 292
Warfarin, as thromboprophylaxis, 118–120,
121t
Wound healing
adjuvant therapy in, 93–95
collaborative models for, 99–100
management of venous leg ulcers in,
91–93
with negative pressure dressings,
108–109
treatment adherence in, 96–99
X
Xenografts, for venous ulcers, 93
Z
Zinc paste bandages, for venous ulcers,
83–84, 83f
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана